Residency · Residency · Medical Genetics Genomics
Skeletal Dysplasias: A Systematic Approach
Introduction
Skeletal dysplasias (osteochondrodysplasias) comprise over 460 distinct conditions affecting bone and cartilage development. The 2023 Nosology and Classification of Genetic Skeletal Disorders organizes these into 42 groups based on clinical, radiographic, and molecular criteria. A systematic approach to evaluation is essential for timely and accurate diagnosis.
Classification Framework
Organizational Principles
Skeletal dysplasias are grouped by shared clinical features, radiographic patterns, and molecular pathways. Major categories include disorders of epiphyseal development (such as multiple epiphyseal dysplasia), metaphyseal development (such as metaphyseal chondrodysplasias), diaphyseal modeling (such as Camurati-Engelmann disease), spine (such as spondyloepiphyseal dysplasias), and growth plate regulation (such as the achondroplasia group).
High-Yield Groups
The FGFR3 disorders include achondroplasia, hypochondroplasia, thanatophoric dysplasia, and SADDAN. The type II collagenopathies (COL2A1) span a continuum from lethal achondrogenesis type II to mild Stickler syndrome type I. Sulfation disorders include diastrophic dysplasia, atelosteogenesis type 2, and achondrogenesis type 1B, all caused by SLC26A2 variants. Filamin disorders encompass FLNB-related conditions (Larsen syndrome, atelosteogenesis types I/III) and FLNA-related conditions (frontometaphyseal dysplasia, otopalatodigital spectrum).
| Gene/Pathway Group | Conditions (Mild → Severe) | Key Radiographic Features | Inheritance |
|---|---|---|---|
| FGFR3 | Hypochondroplasia → Achondroplasia → SADDAN → Thanatophoric dysplasia | Rhizomelic shortening; narrow interpedicular distance; squared iliac wings | AD (gain-of-function) |
| COL2A1 (type II collagenopathies) | Stickler type I → SED congenita → Kniest → Achondrogenesis type II | Platyspondyly; delayed ossification; short trunk | AD |
| SLC26A2 (sulfation disorders) | Multiple epiphyseal dysplasia → Diastrophic dysplasia → Achondrogenesis type IB | Hitchhiker thumb; cauliflower ear; epiphyseal delay | AR |
| FLNB (filamin B) | Larsen syndrome → Atelosteogenesis type I/III | Joint dislocations; cervical vertebral abnormalities | AD or AR |
| COL1A1/A2 (type I collagen) | Mild OI → Severe/lethal OI | Osteopenia; fractures; Wormian bones | AD (or AR for rare forms) |
Systematic Diagnostic Approach
Step 1: Clinical Assessment
The initial evaluation focuses on proportionality (short-limbed -- whether rhizomelic, mesomelic, or acromelic -- versus short-trunk versus proportionate short stature). Limb measurements include the upper-to-lower segment ratio and arm span-to-height ratio. Craniofacial features such as macrocephaly, midface hypoplasia, cleft palate, and micrognathia are documented. Hand and foot findings including brachydactyly, polydactyly, hitchhiker thumb, and trident hand provide diagnostic clues. Associated features such as hearing loss, myopia, cleft palate, and joint contractures or laxity are recorded.
Step 2: Skeletal Survey
A complete skeletal survey is the cornerstone of radiographic evaluation and must include AP and lateral skull, AP and lateral entire spine, AP pelvis, AP long bones of upper and lower extremities, and AP hands (with feet if clinically indicated).
Step 3: Radiographic Pattern Recognition
Platyspondyly (flattened vertebral bodies) suggests spondyloepiphyseal dysplasias or Morquio syndrome. Rhizomelic shortening points to achondroplasia or rhizomelic chondrodysplasia punctata. Metaphyseal irregularity characterizes Schmid metaphyseal chondrodysplasia and cartilage-hair hypoplasia. Epiphyseal stippling (chondrodysplasia punctata) occurs in peroxisomal disorders, warfarin embryopathy, and Conradi-Hunermann syndrome. A narrow thorax suggests asphyxiating thoracic dysplasia (Jeune), Ellis-van Creveld syndrome, or short-rib polydactyly syndromes.
Step 4: Molecular Testing
Targeted single gene or gene panel testing is appropriate when clinical and radiographic features point to a specific group. Exome sequencing is used for atypical or unclassified presentations. Genome sequencing is considered when structural variants or deep intronic variants are suspected. Prenatal testing with trio exome is increasingly utilized for severe skeletal dysplasias detected on ultrasound.
Achondroplasia: The Paradigm
Achondroplasia is the most common non-lethal skeletal dysplasia, occurring in approximately 1 in 15,000-40,000 births. It is caused by a recurrent gain-of-function variant in FGFR3 (p.Gly380Arg in more than 98% of cases). Inheritance is autosomal dominant with complete penetrance, and approximately 80% arise de novo. Clinical features include rhizomelic short stature, macrocephaly, frontal bossing, midface hypoplasia, trident hand, and lumbar lordosis. Complications include foramen magnum stenosis, spinal stenosis, obstructive sleep apnea, recurrent otitis media, and tibial bowing.
Vosoritide (C-Type Natriuretic Peptide Analog)
Vosoritide is the first targeted therapy approved for achondroplasia (FDA 2021, EMA 2021). It is administered as a daily subcutaneous injection for children aged 5 years and older with open growth plates. The mechanism involves antagonizing FGFR3-mediated MAPK signaling, thereby restoring growth plate chondrocyte proliferation and differentiation. The Phase 3 trial demonstrated an increase in annualized growth velocity of approximately 1.57 cm/year over placebo.
Lethal and Severe Skeletal Dysplasias
Thanatophoric dysplasia is the most common lethal skeletal dysplasia, caused by FGFR3 variants (p.Arg248Cys, p.Lys650Glu), and presents with severely shortened limbs, narrow thorax, and cloverleaf skull (in Type II). Achondrogenesis encompasses types IA (TRIP11), IB (SLC26A2), and II (COL2A1), all presenting with severe micromelia and deficient ossification. Short-rib polydactyly syndromes fall within the ciliopathy spectrum, involving genes such as DYNC2H1, WDR35, and IFT80. Prenatal detection by ultrasound is often possible by 18-20 weeks gestation, with findings including shortened long bones, narrow thorax, and polyhydramnios.
Multidisciplinary Care Model
Orthopedics addresses limb lengthening (controversial), spinal decompression, and guided growth. Neurosurgery performs foramen magnum decompression in achondroplasia when indicated. Pulmonology and sleep medicine evaluate for obstructive sleep apnea and thoracic insufficiency. ENT manages hearing assessment and middle ear disease. Genetics provides diagnosis, counseling, surveillance protocols, and coordination of care. Psychosocial support includes advocacy, support groups (such as Little People of America), and accommodations.
Clinical Pearls
A complete skeletal survey is indispensable and should not be replaced by limited radiographs; pattern recognition across multiple skeletal regions drives diagnosis. Proportionality assessment (rhizomelic versus mesomelic versus short-trunk) is the most useful initial clinical discriminator. Many skeletal dysplasias have systemic manifestations (hearing, vision, cardiac, renal) that require anticipatory surveillance beyond skeletal concerns alone. Vosoritide represents a paradigm shift in achondroplasia management as the first molecularly targeted therapy for a skeletal dysplasia.
References
- Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2023 revision. American Journal of Medical Genetics Part A. 2023;191(5):1164-1209.
- Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396(10252):684-692.
- Spranger JW, Brill PW, Hall C, et al. Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 4th ed. Oxford University Press; 2018.
- Wright MJ, Irving MD. Clinical management of achondroplasia. Archives of Disease in Childhood. 2012;97(2):129-134.